我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

陕西汉族PCI术后人群CYP2C19基因多态性分析

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2016年第4期
页码:
439-442
栏目:
临床研究
出版日期:
2016-04-01

文章信息/Info

Title:
Genetic polymorphism analysis of CYP2C19 in Shaanxi Han population after percutaneous coronary intervention
作者:
白晓丹1; 赵 超2; 邓小萍1; 刘琳娜1
(第四军医大学:1.唐都医院药剂科，陕西 西安 710038，2.西京医院药剂科，陕西 西安 710032）
Author(s):
BAI Xiao-dan1;  ZHAO Chao2;  DENG Xiao-ping1;  LIU Lin-na1
(1.Department of Pharmacy, Tangdu Hospital, Fourth Military Medical University, Xi’an 710038, Shaanxi, China；
2.Department of Pharmacy, Xijing Hospital, Fourth Military Medical University, Xi’an 710032, Shaanxi, China)
关键词:
细胞色素2C19; 基因多态性; 陕西汉族; 氯吡格雷
Keywords:
CYP2C19;  genetic polymorphism;  Shaanxi Han population;  clopidogrel
分类号:
R446；R446.11
DOI:
-
文献标识码:
A
摘要:
目的 描述陕西省汉族PCI术后人群的细胞色素2C19(CYP2C19)基因型分布特征。方法 采用个体化基因诊断芯片技术对1 220例陕西汉族PCI术后人群进行CYP2C19基因分型检测。结果 陕西汉族术后人群中男性野生基因型比例为34.02%（*1*1），突变杂合子基因型比例为33.61%（*1*2和1*3），突变纯合子基因型比例为9.43%（*2*2、*2*3和*3*3）。女性野生基因型比例为9.34%（*1*1），突变杂合子基因型比例为11.23%（*1*2和1*3），突变纯合子基因型比例为2.38%（*2*2、*2*3和*3*3）。 结论 陕西汉族PCI术后人群CYP2C19基因多态性以野生型纯合子*1*1和突变杂合子*1*2为主。
Abstract:
AIM To study the characteristics of CYP2C19 genotype in Shaanxi Han population after percutaneous coronary intervention (PCI) and establish a foundation for individualized treatment. METHODSGenotyping of CYP2C19 in 1 220 Shaanxi Han patients after PCI were determined by gene chip. RESULTSAccording to genotyping results, the frequencies of wild type (WT) *1*1 in Shaanxi Han population were 34.02%, WT *1*2 and *1*3 were 33.61%, and WT *2*2, *2*3 and *3*3 were 9.43% in males. The frequencies of WT *1*1 were 9.34%, WT *1*2 and *1*3 were 11.23%, and WT *2*2, *2*3 and *3*3 were 2.38% in females. CONCLUSIONGenetic polymorphism analysis of CYP2C19 WT *1*1 and *1*2 in Shaanxi Han population after PCI are most frequent.

参考文献/References

[1] Prasad A,Holmes DR.Update on dual antiplatelet therapy for percutaneous coronary intervention[J].Heart,2009, 95(11):861-865.
[2]Uchiyama S.Clopidogrel Resistance:Identifying and overcoming a barrier to effective antiplatelet treatment[J]Cardiovasc Ther,2011,29(6):e100-e111.
[3]Park KW,Park JJ,Jeno KH,et al.Enhanced clopidogrel responsiveness in smokers, nullsmokers' paradoxnull is dependent on cytochrome P450 CYP1A2 status[J].Arterioscler Thromb Vasc Biol,2011,31(3):665-671.
[4]Owusu Obeng A,Egelund EF,Alsultan A,et al.CYP2C19 polymorphisms and therapeutic drug monitoring of voriconazole: are we ready for clinical implementation of pharmacogenomics[J].Pharmacotherapy,2014,34(7):703-718.
[5]Sofi F,Giusti B,Marcucci R,et al.Cytochrome P450 2C19*2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis[J].Pharmacogenomics J,2011,11(3):199-206.
[6]Pettersen AA,Arnesen H,Opstad TB,et al.The influence of CYP2C19*2 polymorphism on platelet function testing during single antiplatelet treatment with clopidogrel[J].Thromb J,2011,22(9):4-7.
[7]Zhou J,Lv H,Kang XX.Genetic polymorphism analysis of cytochrome P450 2C19 among gender, age and body mass index in Chinese Han population[J].Chin J Clin Pharmacol Ther,2007,12 (2):208-213.
[8]郭志强，贾正平，马 骏，等.甘肃汉族人群细胞色素P_(450)2C19基因多态性分析[J].中国药房,2010(14):1285-1287.
[9]简 斌.云南汉族人群CYP2C19基因多态性及其对氯吡格雷的疗效影响[J].昆明:昆明医科大学,2013.
[10]范 岚，张 伟，周宏灏.抗血小板药物的遗传药理学研究进展[J].中国药理学通报,2010,26(4):421-424.
[11]Holmes DR Jr,Dehmer GJ,Kaul S,et al.ACCF/AHA clopidogrel clinical alert:approaches to the FDA“boxed warning”:a report of theAmerican College of Cardiology Foundation Task Force on clinical expert consensusdocuments and the American Heart Association endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons[J].J Am Coll Cardiol,2010,56(4):321-341.
[12]Aradi D,Tronyos A,Pinter T,et al.Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel[J].J Am Coll Cardiol,2014,63(11):1061-1070.
[13]Kohli P,Wallentin L,Reyes E,et al.Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO Study[J].Circulation,2013,127(6):673-680.

备注/Memo

备注/Memo:
收稿日期：2015-09-20.
通讯作者：刘琳娜，副主任药师，主要从事中药药理与分子药理研究 Email：liulinna @fmmu.edu.cn
作者简介：白晓丹，药师，硕士 Email：xunzhaojane@163.com
更新日期/Last Update: 2016-04-01